Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osamu Inagaki

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 2, 2013
[Expectation for the drug development activity in academia]Osamu Inagaki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 26, 2016
[Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility]Osamu Inagaki
European Journal of Pharmacology|February 15, 2003
Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in ratsTakeyuki Yatsu, Motonori Aoki, Osamu Inagaki
British Journal of Pharmacology|October 3, 2002
Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamstersTohru Ugawa, Hirotoshi Kakuta, Hiroshi Moritani, et al.
Biological & Pharmaceutical Bulletin|February 3, 2005
Comparison between YM099 and captopril in rats with renal mass reduction-induced progressive renal diseaseTakeyuki Yatsu, Motonori Aoki, Wataru Uchida, et al.
British Journal of Pharmacology|May 15, 2003
YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodentsTohru Ugawa, Hirotoshi Kakuta, Hiroshi Moritani, et al.
Biological & Pharmaceutical Bulletin|July 23, 2002
Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in ratsTomoko Oka-Akagi, Akira Fujimori, Masayuki Shibasaki, et al.
Pharmacological Research|February 20, 2003
Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reductionTakeyuki Yatsu, Masanao Sanagi, Akira Fujimori, et al.
Thrombosis and Haemostasis|September 6, 2003
Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosisTomihisa Kawasaki, Masatoshi Taniguchi, Yumiko Moritani, et al.
European Journal of Pharmacology|April 9, 2002
Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonistYumiko Moritani, Kazuo Sato, Takeshi Shigenaga, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 2, 2013
[Expectation for the drug development activity in academia]Osamu Inagaki
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 26, 2016
[Importance of Post-Marketing Studies in Gathering of Clinical Evidences for Proper Usage of Anti-Cancer Drugs, and the StudyRequirements for Their Credibility]Osamu Inagaki
European Journal of Pharmacology|February 15, 2003
Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in ratsTakeyuki Yatsu, Motonori Aoki, Osamu Inagaki
British Journal of Pharmacology|October 3, 2002
Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamstersTohru Ugawa, Hirotoshi Kakuta, Hiroshi Moritani, et al.
Biological & Pharmaceutical Bulletin|February 3, 2005
Comparison between YM099 and captopril in rats with renal mass reduction-induced progressive renal diseaseTakeyuki Yatsu, Motonori Aoki, Wataru Uchida, et al.
British Journal of Pharmacology|May 15, 2003
YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodentsTohru Ugawa, Hirotoshi Kakuta, Hiroshi Moritani, et al.
Biological & Pharmaceutical Bulletin|July 23, 2002
Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in ratsTomoko Oka-Akagi, Akira Fujimori, Masayuki Shibasaki, et al.
Pharmacological Research|February 20, 2003
Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reductionTakeyuki Yatsu, Masanao Sanagi, Akira Fujimori, et al.
Thrombosis and Haemostasis|September 6, 2003
Antithrombotic and thrombolytic efficacy of YM-254890, a G q/11 inhibitor, in a rat model of arterial thrombosisTomihisa Kawasaki, Masatoshi Taniguchi, Yumiko Moritani, et al.
European Journal of Pharmacology|April 9, 2002
Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonistYumiko Moritani, Kazuo Sato, Takeshi Shigenaga, et al.
Pageof 1